RSSOriginal Research

Therapeutic Potential of Ponesimod Alone and in Combination with Dimethyl Fumarate in Experimental Models of Multiple Sclerosis

Therapeutic Potential of Ponesimod Alone and in Combination with Dimethyl Fumarate in Experimental Models of Multiple Sclerosis

| March 1, 2019

by Laetitia Pouzol, MSc, PharmD; Luca Piali, PhD; Claude CA Bernard, PhD; Marianne M. Martinic, PhD; Beat Steiner, PhD; and Martine Clozel, MD Drs. Pouzol and Clozel were with Actelion Pharmaceuticals Ltd. in Allschwil, Switzerland, at the time of this research, and are presently with Idorsia Pharmaceuticals Ltd. in Allschwil, Switzerland. Dr. Piali was with […]

Continue Reading

Exploring the Potential Psychiatric Implications of Astronomical Phenomena

Exploring the Potential Psychiatric Implications of Astronomical Phenomena

| January 1, 2019

Continue Reading

Validation of an Equation Model to Predict Intracranial Pressure in Clinical Studies

Validation of an Equation Model to Predict Intracranial Pressure in Clinical Studies

| November 1, 2018

Continue Reading

Does Vitamin D Deficiency Contribute to Cognitive Dysfunction in Patients with Systemic Lupus Erythematosus?

Does Vitamin D Deficiency Contribute to Cognitive Dysfunction in Patients with Systemic Lupus Erythematosus?

| October 1, 2018

Continue Reading

Atypical Neuroleptic Malignant Syndrome Precipitated By Clozapine And Quetiapine Overdose: A Diagnostic Challenge

Atypical Neuroleptic Malignant Syndrome Precipitated By Clozapine And Quetiapine Overdose: A Diagnostic Challenge

| July 1, 2018 | 0 Comments

Continue Reading

Implementation of the Electronic Columbia-Suicide Severity Rating Scale (eC-SSRS™) Across Four Phase IIIB Clinical Trials in HIV-Infected Individuals (ARIA, STRIIVING, DAWNING and INSPIRING)

Implementation of the Electronic Columbia-Suicide Severity Rating Scale (eC-SSRS™) Across Four Phase IIIB Clinical Trials in HIV-Infected Individuals (ARIA, STRIIVING, DAWNING and INSPIRING)

| July 1, 2018 | 0 Comments

Continue Reading

Effects of Lisdexamfetamine Dimesylate on Functional Impairment Measured on the Sheehan Disability Scale in Adults With Moderate-to-severe Binge Eating Disorder: Results from Two Randomized, Placebo-controlled Trials

Effects of Lisdexamfetamine Dimesylate on Functional Impairment Measured on the Sheehan Disability Scale in Adults With Moderate-to-severe Binge Eating Disorder: Results from Two Randomized, Placebo-controlled Trials

| May 1, 2018 | 0 Comments

by David V. Sheehan, MD, MBA; Maria Gasior, MD, PhD; Susan L. McElroy, MD; Jana Radewonuk, MSc; Barry K. Herman, MD, MMM; and James Hudson, MD, ScD Dr. Sheehan is with the University of South Florida College of Medicine in Tampa, Florida. Drs. Herman and Gasior and Ms. Radewonuk are formerly affiliated with Shire Pharmaceuticals […]

Continue Reading

Combination Phentermine–Topiramate Extended Release for the Treatment of Binge Eating Disorder: An Open-Label, Prospective Study

Combination Phentermine–Topiramate Extended Release for the Treatment of Binge Eating Disorder: An Open-Label, Prospective Study

| May 1, 2018 | 0 Comments

Continue Reading

Audio Recording for Independent Confirmation of Clinical Assessments in Generalized Anxiety Disorder

Audio Recording for Independent Confirmation of Clinical Assessments in Generalized Anxiety Disorder

| April 1, 2018 | 0 Comments

by Steven D. Targum, MD; Christopher Murphy, PhD; Jibran Khan, BA; Laura Zumpano, BA; Mark Whitlock, PhD; Arthur A. Simen, MD, PhD; and Brendon Binneman, MD†  Drs. Targum and Murphy are with Bracket Global LLC in Boston, Massachusetts. Dr. Khan was with Bracket Global LLC in Boston, Massachusetts, at the time of this study. Ms. […]

Continue Reading